Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance

Bristol Myers Squibb (NYSE:BMY) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 6.050-6.350 for the period, compared to the consensus earnings per share estimate of 6.040. The company issued revenue guidance of $46.0 billion-$47.5 billion, compared to the consensus revenue estimate of $44.2 billion.

Bristol Myers Squibb Price Performance

Shares of BMY traded up $1.81 during mid-day trading on Thursday, hitting $59.43. The company’s stock had a trading volume of 23,919,836 shares, compared to its average volume of 13,429,923. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The stock has a market capitalization of $120.99 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 0.17 and a beta of 0.29. The firm has a 50-day moving average price of $53.88 and a 200 day moving average price of $48.85. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. Bristol Myers Squibb’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BMY shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Wells Fargo & Company increased their price objective on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Finally, Citigroup reaffirmed a “neutral” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Tuesday, January 27th. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $57.43.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue beat and growth‑portfolio strength: BMY reported roughly $12.5B in Q4 revenue with its Growth Portfolio up ~16%, helping offset declines in older drugs — a primary reason markets cheered the print. Article Title
• Positive Sentiment: Upbeat FY‑2026 guidance: Management set EPS guidance of $6.05–$6.35 and revenue guidance of $46.0–$47.5B, above Street revenue expectations — the stronger forward guide is a key catalyst for the rally. Article Title
• Positive Sentiment: Manufacturing capacity deal supports cell/gene pipeline: BMS expanded a multi‑year commercial supply agreement with OXB for lentiviral vectors for its CAR‑T programs — improves execution risk for future cell‑therapy revenue. Article Title
• Positive Sentiment: Analyst/media bullishness: Several outlets and analysts framed the report and guide as bullish (calls of a buy zone and exciting forward setup), which can amplify investor demand. Article Title
• Neutral Sentiment: Market context and sentiment drivers: Broader market/earnings calendar and a slightly weaker weekly jobless claims print are background noise that can affect intraday volatility but don’t change company fundamentals. Article Title
• Neutral Sentiment: “Real catalyst” commentary: Several pieces note that meaningful upside catalysts (pipeline readouts/launches) are still ahead — positive long term but uncertain timing. Article Title
• Negative Sentiment: Mixed EPS and legacy headwinds: Non‑GAAP EPS of $1.26 was below some reported consensus figures and remains materially lower than last year’s $1.67, reflecting ongoing pressures from legacy products. Article Title
• Negative Sentiment: Legacy drug declines remain a drag: Coverage notes that older products continue to decline and margin/earnings comparisons are challenging until growth launches scale. Article Title

Institutional Investors Weigh In On Bristol Myers Squibb

Several institutional investors and hedge funds have recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new position in Bristol Myers Squibb in the 3rd quarter valued at $36,000. Turning Point Benefit Group Inc. bought a new position in Bristol Myers Squibb in the 3rd quarter worth $40,000. Quarry LP acquired a new position in Bristol Myers Squibb during the 3rd quarter worth $48,000. Finally, WFA of San Diego LLC bought a new stake in Bristol Myers Squibb during the second quarter valued at about $49,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.